Cureus:减轻拔管反应药理剂对拔管质量的影响

2020-02-19 不详 网络

已经尝试了几种药物来抑制血液动力学拔管反应,但是所有药物都有可变的副作用,可能会影响短期恢复的质量。本研究旨在评估药理作用,例如右美托咪定,局部麻醉剂等,以减轻或减轻对拔管质量的影响,根据是否存在咳嗽,镇静和喉痉挛/接受全身麻醉的成年患者的支气管痉挛。第二个目的是评估这些药物对拔管后其他立即并发症的影响,例如呼吸抑制,去饱和,心动过缓,低血压以及恶心和呕吐(PONV)。这是对带有荟萃分析的(随机对

已经尝试了几种药物来抑制血液动力学拔管反应,但是所有药物都有可变的副作用,可能会影响短期恢复的质量。本研究旨在评估药理作用,例如右美托咪定,局部麻醉剂等,以减轻或减轻对拔管质量的影响,根据是否存在咳嗽,镇静和喉痉挛/接受全身麻醉的成年患者的支气管痉挛。第二个目的是评估这些药物对拔管后其他立即并发症的影响,例如呼吸抑制,去饱和,心动过缓,低血压以及恶心和呕吐(PONV)。

这是对带有荟萃分析的(随机对照试验)RCT的系统评价。搜索在线医学文献分析和检索系统(MEDLINE),护理和相关健康文献的累积指数(CINAHL)和对照试验的Cochrane中央登记册(CENTRAL),以查找有关药理剂对血流动力学拔管的影响的RCT。反应以及拔管的质量。

对纳入24项研究中的14项进行了荟萃分析。与对照组相比,干预组咳嗽的可能性较小(OR 0.26,95%CI 0.15至0.46,p <0.00001,I2 = 35%)。镇静,低血压(OR = 10.47; 95%CI:1.86,58.80,p = 0.008,I2 = 0%)和心动过缓(OR = 6.57; 95%CI:2.09,20.64,p = 0.001,I2 = 0%)有右美托咪定报道。只有一项研究报道了右美托咪定引起的喉痉挛,而两项研究涉及阿片类药物。

总之,右美托咪定0.4至0.5 ug/kg与平稳拔管,最小的咳嗽,无喉痉挛/支气管痉挛以及稳定的血液动力学有关,而不会引起呼吸抑制,PONV和去饱和。但是,高剂量(大于0.5 ug/kg)会引起心动过缓,低血压和镇静作用。其他药物,例如局部麻醉药,钙通道阻滞剂和阿片类药物,不能减轻拔管引起的咳嗽。

原始出处:

Salim B, Rashid S, et al., Effect of Pharmacological Agents Administered for Attenuating the Extubation Response on the Quality of Extubation: A Systematic Review. Cureus. 2019 Dec 20;11(12):e6427. doi: 10.7759/cureus.6427.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783933, encodeId=560a1e839330a, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Aug 26 23:17:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016848, encodeId=07612016848c7, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Mon Jun 29 11:17:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468895, encodeId=4686146889507, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Fri Feb 21 13:17:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-08-26 徐岩
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783933, encodeId=560a1e839330a, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Aug 26 23:17:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016848, encodeId=07612016848c7, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Mon Jun 29 11:17:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468895, encodeId=4686146889507, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Fri Feb 21 13:17:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-06-29 jiadan198782
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783933, encodeId=560a1e839330a, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Aug 26 23:17:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016848, encodeId=07612016848c7, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Mon Jun 29 11:17:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468895, encodeId=4686146889507, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Fri Feb 21 13:17:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-02-21 steven_u4